X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Holly Campbell

Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Recent Posts

More evidence that medicine prices are growing at slowest rate in decades

By Holly Campbell  |    October 4, 2019
This week the White House Council of Economic Advisers (CEA) released yet another report showing that medicine prices are growing at the slowest rate in decades. The report, “Measuring...   Read More

The truth about the marketing and promotion of medicines

By Holly Campbell  |    October 3, 2019
Despite what critics say, the U.S. biopharmaceutical industry spends three times more on the research and development (R&D) of new treatments and cures than on the marketing and promotion of...   Read More

Survey shows out-of-pocket costs top health care concern for voters

By Holly Campbell  |    October 2, 2019
A recent national survey of 800 registered voters conducted by Public Opinion Strategies shows that health insurance premiums, deductibles and copays are the top health care concerns for...   Read More

Study finds hospitals continue to mark up medicines up to 500% of their cost

By Holly Campbell  |    July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....   Read More

Three reasons why the latest Rx Savings Solutions analysis is misleading

By Holly Campbell  |    July 2, 2019
Yesterday, multiple news outlets featured data from Rx Savings Solutions on medicine price trends. These data reflect list price increases, ignoring the significant rebates and discounts on...   Read More

86 percent of AARP members support the Medicare rebate rule that AARP opposes

By Holly Campbell  |    June 12, 2019
Eighty-six percent of AARP members support the administration’s proposed rule to reform the rebate system in Medicare Part D, according to a nationwide Morning Consult survey commissioned by the...   Read More

New report finds 15 new oncology therapies launched last year

By Holly Campbell  |    June 5, 2019
A record 15 new oncology therapeutics launched in 2018 for 17 tumor types, according to IQVIA’s “Global Oncology Trends 2019” report. This progress includes a continued shift toward precision...   Read More

New study finds hospitals continue to push patients to costlier outpatient settings

By Holly Campbell  |    May 13, 2019
A new study from the Health Care Cost Institute found that, for commercially insured patients, almost 50 percent of medicines administered by physicians, including treatments for diseases like...   Read More

4 Things to know about the IQVIA “Medicine Use and Spending” report

By Holly Campbell  |    May 9, 2019
Today, IQVIA released its Medicine Use and Spending in the U.S. – A Review of 2018 and Outlook to 2023 report – highlighting the drivers behind medicine price and spending trends, patient...   Read More

Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”

By Holly Campbell  |    May 9, 2019
Reinforcing our industry’s commitment to providing patients with more transparency about medicine costs, yesterday, our member companies announced the launch of the Medicine Assistance Tool, or MAT   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates